The Narke Capital Group

Australian Aborigine with a baby kangaroo in 1955.

**Building Memories by the Shore** There’s something timeless about creating sandcastles by the ocean. The gentle breeze, the sound of the waves, and the feeling of the sand between your fingers all come together to make a perfect moment. These photos capture a beautiful day spent on the beach, where creativity met nature in the form of these charming sandcastles. 🌊🏰 Share your favorite beach memories with us in the comments! #BeachLife #SandcastleArt #OceanBreeze #SummerDays #BeachFun #NatureAndCreativity Enkrisi Edward Narke

Great to meet All! Edward Narke

Earlier this year, @cantorfitzgerld highlighted the unique aspects of the San Diego biotech hub, which include the presence of "scrappy" innovators, a balanced approach to innovation, a rich academic ecosystem, a strong presence of pharma R&D and more: bit.ly/45hqnrA

The Range Rover Sport commercial "Spillway" was filmed at the Kárahnjúkar Dam in Iceland, which is the world's largest dam of its kind. The commercial features a world-first climb up the 193-meter dam spillway, which is filled with 750 tonnes of water per minute. The Range Rover Sport must resist the water and avoid losing traction as it descends the 90-meter drop at the base of the spillway.

Enkrisi

The biotech IPO landscape, as detailed by industry analysts Ben Fidler and Gwendolyn Wu, highlights a decade-long period where biotech firms found Wall Street's doors wide open, driven by scientific breakthroughs and the tangible successes of companies in delivering new treatments. The peak of this trend was observed in 2021, with over 100 biotechs making their market debut, collectively raising nearly $15 billion—a testament to the robust appetite for investment in biotech innovation. However, the transition from 2021 into 2022 marked a significant shift, with a downturn across the sector leading to a dramatic fall in the stock prices of newly public companies. This downturn not only cooled the pace of IPOs but also underscored the volatile nature of the biotech industry's relationship with public markets. In the wake of this shift, only 19 drugmakers managed to price initial share sales last year, illustrating a more challenging landscape for emerging biotechs aiming for public market entry. This evolving scenario raises pertinent questions about the future of biotech IPOs. Which emerging biotechs will navigate the challenging path to the public markets successfully? Which will manage to create value, and which will falter? Furthermore, the types of companies that earn the best returns, their investors, and the strategies that underpin successful transitions from private to public entities are of keen interest to stakeholders across the biotech ecosystem. Edward Narke Enkrisi

We have a Big Announcement Tomorrow! Stay Tuned! Enkrisi Edward Narke

The greatest wealth is created by being an early investor in #Innovation Making that investment requires believing in something before the majority of people understand it You will be mocked, ridiculed & criticized for your non-consensus action It is absolutely worth it!

After more than two years in the doldrums, initial public offerings, an important indicator of the biotechnology industry’s health, have shown signs of life. Enkrisi